Tetrahydro-2-furoic acid (CAS 16874-33-2)

DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin), also known as CD209, is a type II transmembrane receptor primarily expressed on the surface of dendritic cells and macrophages. It plays a pivotal role in the immune system by recognizing and binding to specific carbohydrate structures on the surface of pathogens, including viruses, bacteria, and fungi. This recognition is crucial for the initiation of antigen presentation and the subsequent activation of T cells, forming an integral part of the adaptive immune response. DC-SIGN′s ability to bind to a wide range of pathogens, including HIV-1, Ebola, and Dengue virus, underscores its significance in pathogen recognition and immune defense mechanisms. Beyond pathogen recognition, DC-SIGN is involved in modulating immune responses through its signaling pathways; it can either enhance or dampen immune responses depending on the context and type of interaction. The signaling cascades triggered by DC-SIGN include activation of NF-κB and other transcription factors, influencing cytokine production, cell migration, and other immune regulatory functions, thereby playing a complex role in shaping the immune response. Targeting DC-SIGN/CD209 for disruption or inhibition using small molecules allows for a detailed mechanistic characterization of this crucial immune receptor. By using these inhibitors, researchers can explore how DC-SIGN/CD209 mediates the recognition and binding of various pathogens, including viruses and bacteria, and how this affects the subsequent immune response. These small molecules can help delineate the role of DC-SIGN/CD209 in antigen presentation and T cell activation, key processes in adaptive immunity. By observing changes in immune responses when DC-SIGN/CD209 is inhibited, scientists can gain insights into the receptor′s role in modulating immune cell signaling, cytokine production, and cell migration.